Shah, N. J., Campbell, M. T., Mao, S., Ornstein, M. C., Haas, N. B., Gao, X., … Beckermann, K. (2023). 1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy. In Annals of Oncology (Vol. 34, pp. S1016–S1017). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.09.1119

Shah, N. J., M. T. Campbell, S. Mao, M. C. Ornstein, N. B. Haas, X. Gao, H. Hammers, et al. “1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy.” In Annals of Oncology, 34:S1016–17. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.1119.

Shah NJ, Campbell MT, Mao S, Ornstein MC, Haas NB, Gao X, et al. 1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy. In: Annals of Oncology. Elsevier BV; 2023. p. S1016–7.

Shah, N. J., et al. “1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy.” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S1016–17. Crossref, doi:10.1016/j.annonc.2023.09.1119.

Shah NJ, Campbell MT, Mao S, Ornstein MC, Haas NB, Gao X, Hammers H, Keshava-Prasad H, Hoimes CJ, Hussain A, George S, Gourdin TS, Nelson A, Yan H, Esquibel V, McIntyre G, Geller R, Voss MH, Rini BI, Beckermann K. 1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy. Annals of Oncology. Elsevier BV; 2023. p. S1016–S1017.